OpenLobby.EU
Explore

Netherlands Federation of University Medical Centres

NFU

The Netherlands Federation of University Medical Centres (Nederlandse Federatie van Universitair Medische Centra) (NFU) represents the eight cooperating UMCs in the Netherlands, as an advocate for and employer of 65,000 people.

Lobbying Activity

Response to EU Life sciences strategy

17 Apr 2025

See the document attached.
Read full response

Meeting with Rainer Becker (Director Health and Food Safety)

20 Mar 2025 · Presentation on the (future) European policy priorities on medical products and innovation (medicines as well as technologies) to the Executive Boards from all Dutch University Medical Centres

Meeting with Henriette Van Eijl (Head of Unit Research and Innovation), Philippe Cupers (Seconded Head of Unit Research and Innovation) and

20 Mar 2025 · Invitation Netherlands Federation University Medical Centres

Response to Evaluation and revision of the general pharmaceutical legislation

30 Jun 2023

The development of new and innovative pharmaceutical products has become much more research intensive. Most products available are the result of academia delivering new knowledge based on biomedical and chemical research and pharmaceutical companies further developing those novel insights into safe and effective products. Academic pharma focuses on discovering and developing new pharmaceutical products (or targets) as well as repurposing existing ones. Furthermore, an increasing number of products is being developed for specific (and small) subgroups of patients as a solution for rare diseases or personalized medicine. University Medical Centres (UMCs) play a key role in the research and development of these new pharmaceutical products, as well as in the manufacturing of therapies compliant with good manufacturing practice (GMP) and their supply to patients, especially when it comes to advanced therapy medical products (ATMPs), such as cell and gene therapies. These innovations will strongly contribute to the advancement of health care. Although the UMCs fully endorse the ambitions and objectives of the proposed new EU pharmaceutical regulation (COM 2023/193), they have some serious concerns because of the expected negative impact on the European attractiveness for clinical drug trials, academic pharma and small companies, especially compared to the United States. The UMCs express their support to LERUs comments, which we summarize in the Statement attached.
Read full response